InDex Pharmaceuticals Q2: CONCLUDE Proceeding According to Plan - Redeye

Redeye comments on InDex Pharmaceuticals following its Q2 2022 report. The first induction study of CONCLUDE is progressing according to plan, and the company reiterates H2 2023 readout. We will return shortly with a more extended research update where we accommodate for recent news flow, we will also update our financial forecasts and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/853716/index-pharmaceuticals-q222-conclude-proceeding-according-to-plan?utm_source=finwire&utm_medium=RSS